Triglav Investments D.O.O. Reduces Position in Eli Lilly and Company $LLY

Triglav Investments D.O.O. decreased its position in Eli Lilly and Company (NYSE:LLY) by 4.6% during the third quarter, HoldingsChannel.com reports. The firm owned 51,568 shares of the company’s stock after selling 2,468 shares during the quarter. Eli Lilly and Company makes up approximately 2.6% of Triglav Investments D.O.O.’s holdings, making the stock its 9th largest holding. Triglav Investments D.O.O.’s holdings in Eli Lilly and Company were worth $39,343,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Dash Acquisitions Inc. lifted its stake in Eli Lilly and Company by 2.8% during the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock valued at $387,000 after acquiring an additional 13 shares during the period. Nvest Financial LLC increased its holdings in Eli Lilly and Company by 0.6% during the second quarter. Nvest Financial LLC now owns 2,274 shares of the company’s stock valued at $1,773,000 after buying an additional 13 shares during the last quarter. MPS Loria Financial Planners LLC raised its holdings in Eli Lilly and Company by 1.9% in the 2nd quarter. MPS Loria Financial Planners LLC now owns 699 shares of the company’s stock worth $545,000 after purchasing an additional 13 shares during the period. Key Client Fiduciary Advisors LLC increased its position in Eli Lilly and Company by 1.2% in the third quarter. Key Client Fiduciary Advisors LLC now owns 1,136 shares of the company’s stock worth $867,000 after buying an additional 13 shares in the last quarter. Finally, Darwin Wealth Management LLC raised its stake in Eli Lilly and Company by 3.6% during the 3rd quarter. Darwin Wealth Management LLC now owns 373 shares of the company’s stock worth $285,000 after acquiring an additional 13 shares during the period. 82.53% of the stock is owned by institutional investors.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q4 beat and strong 2026 guidance — Lilly reported revenue of $19.3B and EPS above estimates, then guided FY‑26 revenue $80–83B and EPS 33.50–35.00, which underpins the stock rally. Reuters: Lilly sees 2026 profit above estimates
• Positive Sentiment: Surging GLP‑1 sales — Mounjaro and Zepbound volumes doubled+/grew strongly, allowing Lilly to offset U.S. pricing pressure through volume growth. This is the main revenue driver cited by management. CNBC: Lilly blows past quarterly estimates
• Positive Sentiment: Capacity investments support long-term supply advantage — Lilly announced a major $3.5B injectable facility (and broader greenfield buildout), reducing past supply constraints and supporting the volume strategy. MarketBeat: The Metabolic Split
• Neutral Sentiment: Analyst positioning — some firms reaffirm buy ratings and raise targets after the beat, which amplifies momentum but also cements expectations. MarketScreener: Goldman Sachs maintains buy
• Neutral Sentiment: Sector rotation vs. peers — Lilly’s upside is amplified by Novo Nordisk’s weaker guide (investors reallocating within GLP‑1 names), so part of the move reflects relative positioning. Investopedia: Stocks diverge
• Negative Sentiment: Valuation and pullback risk — several analysts/writers warn the stock is priced for perfection and a pullback is possible if execution/sales slow or guidance disappoints relative to very high expectations. Forbes: 3 reasons a pullback is likely
• Negative Sentiment: Pricing/regulatory headwinds remain — U.S. pricing measures (e.g., MFN-type pressures) are real; Lilly is using volume to offset price declines, but continued price compression is a recurring downside risk. Reuters: pricing headwinds noted
• Negative Sentiment: Competition is intensifying — Novo’s new oral and Pfizer/other entrants’ GLP‑1 programs are accelerating; long-term share and pricing could be pressured as more oral/cheaper options scale. MarketBeat: Pfizer GLP-1 results

Eli Lilly and Company Trading Up 10.3%

Shares of NYSE LLY opened at $1,107.13 on Thursday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The business has a fifty day moving average price of $1,054.31 and a 200 day moving average price of $895.30. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The stock has a market capitalization of $1.05 trillion, a P/E ratio of 54.16, a price-to-earnings-growth ratio of 0.76 and a beta of 0.39.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business’s quarterly revenue was up 42.6% on a year-over-year basis. During the same period in the prior year, the firm posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Zacks Research lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a research report on Monday. The Goldman Sachs Group restated a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday. Finally, Morgan Stanley upped their target price on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an “overweight” rating in a research note on Monday, November 24th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $1,162.75.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.